Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus KEFTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus KEFTAB.
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER vs KEFTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cephalexin binds to penicillin-binding proteins (PBPs) on the bacterial cell wall, inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes.
1-2 g IV every 4-6 hours; maximum 12 g/day.
Cefuroxime axetil (KEFTAB) 250-500 mg orally twice daily for 7-10 days. For uncomplicated urinary tract infections: 250 mg twice daily; for acute otitis media: 500 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 0.8-1.4 hours in adults with normal renal function; prolonged to 2.5-15 hours in renal impairment; clinical context: dosing interval adjustment required for CrCl <20 mL/min
0.8-1.2 hours (prolonged to 6-8 hours in renal impairment; requires dose adjustment for CrCl <50 mL/min)
Primarily renal (80-90% unchanged within 24 hours); biliary/fecal elimination accounts for <10%
Renal: 90-95% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic